GlobeNewswire by notified

Invitation to the special and extraordinary shareholders' meetings

Share

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting.

On 14 July 2019, Galapagos NV (the "Company" or "Galapagos") announced that it entered into a collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company. In view hereof, Galapagos has the honor to invite its shareholders, warrant holders, directors, and statutory auditor to its special and extraordinary shareholders' meetings that will be held on Tuesday 22 October 2019 at 2:00 p.m. (CEST) at the Company's registered office.

The items on the agenda of the special and extraordinary general meetings of shareholders include, amongst other things, the appointment of Mr. Daniel O'Day and Dr. Linda Higgins as directors of the Company, the approval of the issuance of two warrants for the benefit of Gilead Therapeutics A1 Unlimited Company, and the renewal of the Company's authorized capital by up to 20% of the share capital.

In order to be admitted to the shareholders' meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code of 7 May 1999 and article 29 of the Company's articles of association, and fulfill the formalities described in the convening notice. The convening notice and other documents pertaining to the shareholders' meetings, including the biographies of Mr. O’Day and Dr. Higgins, can be consulted on our website (www.glpg.com ).

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

  
Contact

Investors: Media:
Elizabeth Goodwin  Carmen Vroonen
VP IR  Senior Director Communications
+1 781 460 1784  +32 473 824 874
   
Sofie Van Gijsel   Evelyn Fox
Director IR  Director Communications
+32 485 19 14 15  +31 6 53 591 999
ir@glpg.com  communications@glpg.com

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Disclaimer
The contents of our website, including the special reports prepared by the board of directors and the statutory auditor at the occasion of the shareholders' meetings of 22 October 2019, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES19.3.2024 09:30:00 CET | Press release

Bid date, 2024-03-19Auction date2024-03-19Settlement date2024-03-20Maturity Date2024-03-27Nominal amount956 billion SEKInterest rate4.00 %Bid times09.30-10.00 (CET/CEST) on the Bid dateBids are made to phone number08-696 69 70Confirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume956 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term956 billion SEKExpected excess liquidity at full allotment0 billion SEK Stockholm, 2024-03-19

Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our fifth VLGC newbuilding19.3.2024 09:20:18 CET | Press release

Hamilton, Bermuda March 19, 2024 Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) announce today the successful sale of newbuilding hull 2367 with intended name Avance Castor for a cash consideration of $120 million less broker commission as previously announced in a press release dated December 8, 2023. The Company expect to record a book gain on sale and cash release following repayment of bank financing of $36 million and $61 million respectively. The sale of the sister ship, newbuilding hull 2368 with intended name Avance Pollux, is scheduled to take place in the first half of May 2024. This sale is also expected to result in a book gain and cash release of $36 million and $60 million respectively. For further queries, please contact: Media contact: Øystein Kalleklev, CEO Tel: +47 23 11 40 00 Investor and Analyst contact: Randi Navdal Bekkelund, CFO Tel: +47 23 11 40 00 ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleu

Offentliggørelse af prospekt for Investeringsforeningen Danske Invest19.3.2024 09:00:00 CET | pressemeddelelse

Vi skal herved oplyse, at der er foretaget ændringer i prospektet for Investeringsforeningen Danske Invest. Prospektet for investeringsforeningen Danske Invest er opdateret med lanceringsdato for afdeling Structured Credit – Investment Grade, Accumulating.Derudover er afsnit 6 ”Afdelingernes/andelsklassernes risici” omformuleret bredere til også at omfatte strukturerede gældsinstrumenter for afdeling Structured Credit – Investment Grade, Accumulating. Prospekterne kan fra i dag ses på www.danskeinvest.dk. Med venlig hilsen DANSKE INVEST MANAGEMENT A/S Tina Hjorth Hetting Head of Fund Products

Danske Bank A/S, transactions by persons discharging managerial responsibilities19.3.2024 08:50:12 CET | Press release

19 March 2024 Notification no. 23/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024-03-15

Danske Bank A/S, ledende medarbejderes transaktioner19.3.2024 08:50:12 CET | pressemeddelelse

19. marts 2024 Indberetning nr. 23/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024-03-15

HiddenA line styled icon from Orion Icon Library.Eye